These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 26003433)

  • 21. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
    Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
    Cairns JA; McMurtry MS
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S60-70. PubMed ID: 23790600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.
    Kang DO; Yu CW; Kim HD; Cho JY; Joo HJ; Choi RK; Park JS; Lee HJ; Kim JS; Park JH; Hong SJ; Lim DS
    Coron Artery Dis; 2015 Aug; 26(5):372-80. PubMed ID: 25768244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
    Lopes RD; Vora AN; Liaw D; Granger CB; Darius H; Goodman SG; Mehran R; Windecker S; Alexander JH
    Am Heart J; 2018 Jun; 200():17-23. PubMed ID: 29898844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.
    Chi G; Yee MK; Kalayci A; Kerneis M; AlKhalfan F; Mehran R; Bode C; Halperin JL; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Peterson ED; Fox KAA; Gibson CM
    J Thromb Thrombolysis; 2018 Oct; 46(3):346-350. PubMed ID: 29943350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
    Lip GYH; Mauri L; Montalescot G; Ozkor M; Vardas P; Steg PG; Bhatt DL; Hohnloser SH; Miede C; Nordaby M; Brueckmann M; Kreuzer J; Kimura T; Oldgren J; Ten Berg JM; Cannon CP
    Am Heart J; 2019 Jun; 212():13-22. PubMed ID: 30928824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation.
    Sammut MA; Conway D; Iqbal J; Krishnamurthy A; Morgan KP; Morris PD; Richardson JD; Rothman AMK; Gunn JP; Storey RF
    Expert Rev Cardiovasc Ther; 2024 Jul; 22(7):339-345. PubMed ID: 38949642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
    Pareek M; Bhatt DL; Ten Berg JM; Kristensen SD; Grove EL
    Expert Opin Pharmacother; 2017 Jun; 18(9):875-883. PubMed ID: 28489475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.
    Mrdovic I; Savic L; Krljanac G; Asanin M; Cvetinovic N; Brdar N; Stojanovic M; Djuricic N; Stankovic S; Marinkovic J; Perunicic J
    J Interv Cardiol; 2013 Jun; 26(3):221-7. PubMed ID: 23373620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Benetou DR; Varlamos C; Ktenas D; Tsiafoutis I; Koutouzis M; Bampali T; Mantis C; Zarifis J; Skalidis E; Aravantinos D; Varvarousis D; Lianos I; Kanakakis J; Pisimisis E; Ziakas A; Davlouros P; Alexopoulos D;
    Cardiovasc Drugs Ther; 2021 Feb; 35(1):11-20. PubMed ID: 33034806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study.
    Yasuda S; Kaikita K; Ogawa H; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K
    Int J Cardiol; 2018 Aug; 265():108-112. PubMed ID: 29764706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
    Thompson PL; Verheugt FW
    Clin Ther; 2014 Sep; 36(9):1176-81. PubMed ID: 25234549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
    Enomoto Y; Iijima R; Tokue M; Ito N; Nagashima Y; Araki T; Yamazaki K; Utsunomiya M; Hori M; Itaya H; Shiba M; Hara H; Nakamura M; Sugi K
    Cardiovasc Interv Ther; 2014 Jul; 29(3):193-9. PubMed ID: 24366503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivaroxaban in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention in Clinical Practice.
    Zeymer U; Toelg R; Wienbergen H; Hobbach HP; Cuneo A; Bekeredjian R; Ritter O; Hailer B; Hertting K; Hennersdorf M; Scholtz W; Lanzer P; Mudra H; Schwefer M; Schwimmbeck PL; Liebetrau C; Thiele H; Claas C; Riemer T; Zahn R
    Am J Cardiol; 2023 Feb; 189():31-37. PubMed ID: 36493580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
    Hermosillo AJ; Spinler SA
    Ann Pharmacother; 2008 Jun; 42(6):790-805. PubMed ID: 18477734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
    Rubboli A; Agewall S; Huber K; Lip GY
    Int J Cardiol; 2015 Oct; 196():133-8. PubMed ID: 26093527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Dabigatran Plus a P2Y
    De Caterina R; Procopio A; Lopez Sendon JL; Raev D; Mehta SR; Opolski G; Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Kleine E; Ten Berg JM; Bhatt DL; Miede C; Nordaby M; Cannon CP;
    Am J Med; 2020 Nov; 133(11):1302-1312. PubMed ID: 32389658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.